Empowering dialysis users and caregivers
Search for dialysis centres here
Log in to explore the world's most comprehensive database of dialysis centres for free!
Professional dialysis recruitment| FDA accepts NDA to review Affymax, Takeda chronic kidney disease drug - Pharmaceutical Business Review |
 |
 |
|
Pharmaceutical Business Review The NDA submission is based on data from two Phase 3 studies (Emerald 1 and 2) which evaluated the efficacy and safety of peginesatide. The study compared once-monthly peginesatide with epoetin in maintaining Hb levels in CKD patients on dialysis with |
